Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BLUSF NASDAQ:EIDX NASDAQ:HRTX NASDAQ:IRWD NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AHRTXHeron Therapeutics$1.29-0.8%$1.30$1.04▼$2.68$238.31M1.251.56 million shs638,534 shsIRWDIronwood Pharmaceuticals$1.43-7.7%$1.31$0.53▼$5.13$251.77M0.31.31 million shs1.05 million shsLGNDLigand Pharmaceuticals$181.65+0.5%$167.66$93.58▼$186.48$3.54B0.95166,914 shs156,792 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%HRTXHeron Therapeutics-0.77%+0.78%+6.61%-33.16%-31.02%IRWDIronwood Pharmaceuticals-7.74%-9.78%+11.72%+86.32%-68.22%LGNDLigand Pharmaceuticals+0.49%+2.21%+9.82%+30.59%+69.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AHRTXHeron Therapeutics$1.29-0.8%$1.30$1.04▼$2.68$238.31M1.251.56 million shs638,534 shsIRWDIronwood Pharmaceuticals$1.43-7.7%$1.31$0.53▼$5.13$251.77M0.31.31 million shs1.05 million shsLGNDLigand Pharmaceuticals$181.65+0.5%$167.66$93.58▼$186.48$3.54B0.95166,914 shs156,792 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%HRTXHeron Therapeutics-0.77%+0.78%+6.61%-33.16%-31.02%IRWDIronwood Pharmaceuticals-7.74%-9.78%+11.72%+86.32%-68.22%LGNDLigand Pharmaceuticals+0.49%+2.21%+9.82%+30.59%+69.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUSFBELLUS Health 0.00N/AN/AN/AEIDXEidos Therapeutics 0.00N/AN/AN/AHRTXHeron Therapeutics 2.25Hold$4.50248.84% UpsideIRWDIronwood Pharmaceuticals 2.25Hold$4.94245.45% UpsideLGNDLigand Pharmaceuticals 2.71Moderate Buy$176.50-2.84% DownsideCurrent Analyst Ratings BreakdownLatest LGND, IRWD, HRTX, EIDX, and BLUSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025HRTXHeron TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025IRWDIronwood PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LGNDLigand PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/7/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/6/2025IRWDIronwood PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/27/2025HRTXHeron TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025IRWDIronwood PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LGNDLigand PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/5/2025IRWDIronwood PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/3/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$167.00 ➝ $190.009/2/2025LGNDLigand PharmaceuticalsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$160.00 ➝ $175.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74HRTXHeron Therapeutics$149.69M1.58N/AN/A($0.22) per share-5.86IRWDIronwood Pharmaceuticals$351.41M0.66$0.05 per share31.34($1.88) per share-0.76LGNDLigand Pharmaceuticals$187.58M18.98$1.61 per share112.50$43.95 per share4.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/AEIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/AHRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)IRWDIronwood Pharmaceuticals$880K-$0.05N/A5.72N/A-2.25%-2.46%2.19%11/6/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A48.96N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)Latest LGND, IRWD, HRTX, EIDX, and BLUSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025HRTXHeron Therapeutics-$0.02N/AN/AN/A$39.03 millionN/A11/6/2025Q3 2025IRWDIronwood Pharmaceuticals$0.08N/AN/AN/A$74.22 millionN/A11/6/2025Q3 2025LGNDLigand Pharmaceuticals$1.96N/AN/AN/A$58.71 millionN/A8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million8/7/2025Q2 2025IRWDIronwood Pharmaceuticals-$0.02$0.14+$0.16$0.14$62.02 million$85.24 million8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUSFBELLUS HealthN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUSFBELLUS HealthN/A13.8713.87EIDXEidos Therapeutics0.1411.1011.10HRTXHeron TherapeuticsN/A0.820.53IRWDIronwood PharmaceuticalsN/A0.820.82LGNDLigand PharmaceuticalsN/A5.455.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUSFBELLUS HealthN/AEIDXEidos Therapeutics31.40%HRTXHeron Therapeutics80.01%IRWDIronwood PharmaceuticalsN/ALGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipBLUSFBELLUS Health24.17%EIDXEidos Therapeutics70.10%HRTXHeron Therapeutics5.86%IRWDIronwood Pharmaceuticals12.70%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableHRTXHeron Therapeutics300183.32 million172.57 millionOptionableIRWDIronwood Pharmaceuticals220162.43 million141.81 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableLGND, IRWD, HRTX, EIDX, and BLUSF HeadlinesRecent News About These CompaniesLigand Pharmaceuticals (NASDAQ:LGND) Hits New 12-Month High - Here's WhyOctober 17 at 10:59 AM | marketbeat.comTweedy Browne Co LLC Takes Position in Ligand Pharmaceuticals Incorporated $LGNDOctober 17 at 7:13 AM | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Position Decreased by Blair William & Co. ILOctober 17 at 3:23 AM | marketbeat.comLigand to Host Investor Day on December 9, 2025October 16 at 7:00 AM | globenewswire.comEquitable Trust Co. Acquires 1,710 Shares of Ligand Pharmaceuticals Incorporated $LGNDOctober 16 at 5:00 AM | marketbeat.comAberdeen Group plc Has $26.06 Million Holdings in Ligand Pharmaceuticals Incorporated $LGNDOctober 14, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by AnalystsOctober 13, 2025 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 13, 2025 | marketbeat.comVillere ST Denis J & Co. LLC Has $32.64 Million Position in Ligand Pharmaceuticals Incorporated $LGNDOctober 11, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Earns Sell (D+) Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comLigand partner SQ Innovation receives approval from FDA for Lasix ONYUOctober 9, 2025 | msn.comLigand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure PatientsOctober 9, 2025 | quiverquant.comQLigand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure PatientsOctober 9, 2025 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year High - Here's What HappenedOctober 6, 2025 | marketbeat.comJohn Kozarich Sells 467 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockOctober 4, 2025 | insidertrades.comLigand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 SharesOctober 3, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Purchased by Chicago Capital LLCSeptember 30, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month High - What's Next?September 29, 2025 | marketbeat.comCongress Asset Management Co. Raises Stake in Ligand Pharmaceuticals Incorporated $LGNDSeptember 26, 2025 | marketbeat.comJason Aryeh Sells 10,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockSeptember 25, 2025 | insidertrades.comArecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292September 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLGND, IRWD, HRTX, EIDX, and BLUSF Company DescriptionsBELLUS Health OTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Eidos Therapeutics NASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.Heron Therapeutics NASDAQ:HRTX$1.29 -0.01 (-0.77%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.28 -0.01 (-0.78%) As of 10/17/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Ironwood Pharmaceuticals NASDAQ:IRWD$1.43 -0.12 (-7.74%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.50 +0.07 (+4.90%) As of 10/17/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Ligand Pharmaceuticals NASDAQ:LGND$181.65 +0.88 (+0.49%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$181.76 +0.10 (+0.06%) As of 10/17/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
